Company Filing History:
Years Active: 2013
Title: Annick Ocmant: Innovator in Interferon Treatment Evaluation
Introduction
Annick Ocmant is a notable inventor based in Le Roeulx, Belgium. She has made significant contributions to the field of medical treatment evaluation, particularly concerning type I interferon therapies. Her innovative approach has the potential to enhance treatment outcomes for various conditions.
Latest Patents
Annick Ocmant holds a patent for a method that evaluates the response of an individual to treatment with type I interferon. This method assesses the in vivo presence of factors that may inhibit the biological effects of type I interferon in patients undergoing treatment. The process involves incubating a blood sample with type I interferon and measuring mRNA levels of a biological marker, specifically MxA, to determine the effectiveness of the treatment. This method is particularly relevant for conditions such as multiple sclerosis, HCV, and HBV.
Career Highlights
Throughout her career, Annick Ocmant has worked with esteemed institutions, including Université Libre de Bruxelles. Her research and innovations have contributed to a deeper understanding of interferon treatments and their implications for patient care.
Collaborations
Annick has collaborated with notable colleagues such as Patrick Stordeur and Mathieu Vokaer. Their combined expertise has furthered advancements in the evaluation of treatment responses.
Conclusion
Annick Ocmant's work in evaluating the response to type I interferon treatments showcases her dedication to improving medical therapies. Her innovative methods and collaborations highlight her significant role in the field of medical research.